Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Extraordinary General Meeting

13 Feb 2015 12:23

RNS Number : 8906E
3Legs Resources plc
13 February 2015
 



For Immediate Release

 

13 February 2015

 

 

3Legs Resources plc

 

Results of Extraordinary General Meeting

 

Change of Directors

 

Total Voting Rights

 

 

At the Extraordinary General Meeting of 3Legs Resources plc ("3Legs" or the "Company") held today, all the resolutions contained in the Notice of Extraordinary General Meeting and put to the meeting were passed. All the resolutions were decided by way of a poll. Details of the votes cast were as follows.

 

Resolution

In favour

Against

Withheld

1. To approve the Capital Return (as defined in the circular published by the Company on 27 January 2015 (the "Circular"))

43,741,421

0

0

2. To authorise the directors of the Company to allot and issue 345,025,861 ordinary shares of £0.00025 each at a price of 0.232 pence per share, as if the pre-emption provisions of the Company's articles of association did not apply

43,741,421

0

0

3. To approve the adoption of the Investing Policy (as defined in the Circular)

43,741,421

0

0

4. To generally and unconditionally authorise the directors of the Company to allot ordinary shares of £0.00025 each up to an aggregate par value of £150,000, as if the pre-emption provisions of the Company's articles of association did not apply

34,191,881

0

9,549,540

 

Details of the Capital Return

 

Immediately following the Extraordinary General Meeting, the board of directors reconsidered the Company's solvency position and confirmed the Capital Return at 1.33 pence per qualifying Ordinary Share, equal to approximately £1.145 million in total. Capital return payments of 1.33 pence per Ordinary Share are expected to be made to Qualifying Shareholders (as defined in the Circular) on 20 February 2015.

 

Following completion of the Capital Return, the Company will have returned a total of 19.83 pence per share to shareholders, equal to approximately £17.1 million in all, which is in excess of the indication given by the Company in the circular dated 7 November 2014. Moreover, the two capital returns and associated transactions executed by the Company will result in a faster return of funds to shareholders than would have been achieved by a conventional liquidation process.

 

Details of the Subscription

 

Following the passing of the Resolutions, the Company has issued and allotted 345,025,861 new Ordinary Shares in the Company at a price of 0.232 pence per new Ordinary Share. The net proceeds of the Subscription (as defined in the Circular) will be used in connection with the implementation of the Company's new Investing Policy. Application has been made for the admission of the new Ordinary Shares to trading on AIM which is expected to occur at 8.00 a.m. on 16 February 2015 ("Admission").

 

Following Admission, the Company will have 431,152,590 Ordinary Shares in issue and each share will carry the right to one vote. This number may be used by Shareholders as the denominator for any calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

Change of Directors

 

In accordance with the Company's plans announced on 27 January 2015, Tim Eggar and Kamlesh Parmar will resign as directors and, respectively, Chairman and Chief Executive Officer of the Company with effect from Admission. Richard Armstrong and Colin Weinberg have been appointed directors of the Company with effect from Admission. The information required to be disclosed in accordance with Schedule Two (g) of the AIM Rules for Companies for Mr. Armstrong and Mr. Weinberg is set out below.

 

Richard James Armstrong, aged 67, is or has been in the past five years a director of the following companies:

 

Current Directorships

Past Directorships

Blenheim Wind (UK) plc

Bass Energy Pty Limited

Petrocapital Resources plc

Blenheim Energy Limited

Blenheim Wind and Biomass Limited

Citypoint Investments plc

Devonshire Wind Projects Limited

Ecovista plc

IGas Energy plc

Pires Investments plc

Xchange House plc

Richard Armstrong resigned as a director of Bass Energy Pty Ltd in January 2012. The company was placed into liquidation on 13 December 2012.

 

Upon completion of the Subscription Mr. Armstrong will hold 6,465,517 Ordinary Shares representing 1.5 per cent. of the enlarged share capital of the Company.

 

Colin Lawrence Weinberg, aged 65, is or has been in the past five years a director of the following companies:

 

Current Directorships

Past Directorships

Akoris Trading Limited

Denby Investment (UK) Limited

Aspley Investments Limited

Crayson Limited

Associated British Engineering plc

Atticus Projects Limited

British Polar Engines Limited

Hirst & Mallinson Limited

Kennedy Ventures plc

Zander Group Limited

 

Upon completion of the Subscription Mr. Weinberg will hold 4,310,345 Ordinary Shares representing 1 per cent. of the enlarged share capital of the Company. Mr. Weinberg is a director of British Polar Engines Limited which has subscribed for 86,206,897 Ordinary Shares representing 20 per cent. of the enlarged capital of the Company. 

 

Unless the context otherwise requires, defined terms used in this announcement shall have the meanings given to them in the circular posted to Shareholders on 27 January 2015, which is available to view on the Company's website (www.3legsresources.com).

 

Enquiries:

 

3Legs Resources plc

Tel:

+44 1624 811 611

Kamlesh Parmar, Chief Executive Officer

Alexander Fraser, Chief Financial Officer

Northland Capital Partners Limited

Tel:

+44 207 382 1100

(Nominated Adviser and Broker)

Matthew Johnson

Edward Hutton

FTI Consulting

Tel:

+44 203 727 1000

Oliver Winters

Shannon Brushe

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REGEAAADFAESEFF
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.